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 In this issue of  Kidney International , 
Sekine and colleagues 1 describe the renal 
manifestations in nine patients with the 
R702 mutations in  MYH9 , encoding 
nonmuscle myosin IIA heavy chain. 
Describing patients from diff erent fami-
lies, but with the same mutated amino 
acid residue (R702C and R702H), this 
paper provides genotype – phenotype cor-
relations and makes several useful con-
tributions. First, it underscores the 
rapidity with which chronic kidney dis-
ease can progress to end-stage kidney 
disease in these patients, oft en in less 
than 2 – 3 years. Second, it confi rms ear-
lier reports that angiotensin antagonist 
therapy may reduce proteinuria but does 
not do so in all patients. Th ird, it con-
fi rms prior observations of glomerular 
basement membrane (GBM) pathology. 
Fourth, it demonstrates that the patho-
logic picture can include segmental 
glomerulosclerosis, at an early stage of 
chronic kidney disease, which could 
indicate primary podocyte injury rather 
than post-adaptive focal segmental 
glomerulosclerosis (FSGS) consequent to 
a reduced number of functioning neph-
rons. Fift h, it suggests that  MYH9 protein 
is expressed by podocytes and mesangial 
cells, as previously reported, and also by 
tubular cells (including  proximal, loop of 
Henle, and distal tubules) and endothe-
lial cells (interlobular arteries and arteri-
oles and peritubular capillaries). 
 A set of overlapping syndromes, char-
acterized by macrothrombocytopenia, 
azurophilic D ö hle-like inclusions in neu-
trophils, sensorineural deafness, cata-
racts, and glomerular injury, was linked 
to  MYH9 coding region mutations (mis-
sense, nonsense, and deletions) in 
2000. 2,3 Th e most characteristic fi nding 
is the macrothrombocytopenia; some 
patients have mild to moderate mucocu-
taneous bleeding diathesis, but others 
are unaff ected. Various names have been 
used, including giant platelet syndrome 
(which leads to confusion with other 
genetic causes of giant platelets, including 
Bernard – Soulier syndrome), and non-
muscle myosin IIA disorders (MYHIIA 
syndrome) and  MYH9  disorders. 
Recently,  MYH9 kidney risk variants 
have been associated with HIV-associ-
ated collapsing glomerulopathy, FSGS, 
and hypertension-attributed end-stage 
kidney disease among African-descent 
populations. 4 Th e term  ‘ MYH9 disor-
ders ’ lumps together the autosomal dom-
inant disorders and the kidney risk 
variant. Th erefore a more distinctive 
and precise term is preferred for the 
former category, perhaps autosomal 
dominant  MYH9 (ADM9) spectrum 
disorders. The ADM9 spectrum com-
prises at least five syndromes: May –
 Hegglin anomaly (OMIM 155100), 
Sebastian syndrome (OMIM 606249), 
Epstein syndrome (OMIM 153650), 
Fechtner syndrome (OMIM 153640), 
and isolated  sensorineural deafness 
(OMIM 603622). Glomerular pathology 
has been noted in Epstein and Fechtner 
syndromes, beginning with the original 
reports describing these syndromes. 
 Kidney abnormalities, the subject of a 
recent comprehensive review, 5 are seen in 
about 30 % – 70 % of ADM9 patients. 
Patients may present with microscopic 
hematuria, with or without proteinuria. 
Proteinuria may remain subnephrotic or 
may become nephrotic. Th e combination 
of glomerulopathy, sensorineural deafness, 
and, in some cases, cataracts may mimic 
Alport syndrome, but the other features 
(particularly abnormal platelets and auto-
somal dominant mode of inheritance) 
should aid in the clinical distinction. 
 To date, 39  MYH9 mutations, distrib-
uted across 12 of the 40 coding exons, 
have been associated with ADM9 spec-
trum disorders ( Figure 1 ), tabulated in a 
comprehensive review. 6 Th ese include 26 
missense mutations (codon changing), 
fi ve in-frame deletions, and one dupli-
cation. Also, located in the last exon, 
where a truncated protein is apparently 
tolerated and therefore is non-lethal, are 
two nonsense mutations (resulting in a 
premature stop codon) and fi ve frameshift  
mutations. Several individuals had 
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 multiple  mutations, and so the pathogenic 
mutation is not certain. 6 As shown, 11 
mutations occur in the head domain, and 
the remaining mutations occur in the rod 
domain of the nonmuscle myosin IIA 
heavy chain protein. Four residues have 
been aff ected by multiple missense muta-
tions: R702, R1165, D1424, and R1933. 
Th is observation, together with the fre-
quent occurrence of the same mutation in 
apparently unrelated families and in indi-
viduals with spontaneous mutations, sug-
gests either that there are mutational hot 
spots, or alternatively that certain residues 
are particularly important for myosin 
function and substitutions are not well 
tolerated. Evidence for or against the latter 
may come in the near future, when wide-
spread use of whole-genome sequencing 
makes it possible to study the sequences 
of all genes, from thousands of individuals 
(for example, the ongoing 1000 Genomes 
Project), providing insight into the fre-
quency of rare, phenotypically silent 
mutations across this and other genes. 
 Pecci and colleagues have presented 
comprehensive data addressing geno-
type – phenotype correlation. 7 Of 93 
ADM9 patients, 28 % manifested glomer-
ulopathy and 21 of 44 (48 % ) evaluable 
pedigrees had glomerulopathy. The 
mean onset age was 23 years, with 77 % 
having onset before age 30. Of the com-
monly targeted residues, R702 mutations 
were associated with the highest inci-
dence of glomerulopathy, with half 
aff ected by age 20 and 90 % aff ected by 
age 40. Strikingly, all individuals with 
motor domain mutations develop 
nephritis before age 40, while mutations 
at 1933 in the non-helical tail were asso-
ciated with less kidney disease than 
other mutations in the helical portion of 
the rod domain. 
 Th e molecular mechanisms responsible 
for the renal fi ndings in ADM9 spectrum 
disorders are uncertain. Nonmuscle 
myosin II is expressed in nearly all cells. 
Nonmuscle myosin IIA is normally 
expressed in podocytes (at a high level, by 
immunostaining and  in situ hybridization) 
and mesangial cells (apparently at a 
somewhat lower level) and, as Sekine and 
colleagues suggest, 1 in certain endothelial 
cells and most tubular cells. Th e missense 
mutations might be associated with haploin-
suffi  ciency, which has been shown in plate-
lets with the D1424N mutation, 8 or with a 
dominant-negative phenotype, as has been 
shown in neutrophils. 9 
 Relatively few renal biopsies from 
ADM9 patients have been reported, 
 perhaps in part because of the bleeding 
 Figure 1  |  Nonmuscle myosin IIA structure and  MYH9 exon structure, with autosomal dominant  MYH9 mutations. Above: A schematic of 
nonmuscle myosin IIA, showing the two heavy chains (encoded by  MYH9 ) in blue (comprising 1960 amino acid residues), the two regulatory light 
chains in green, and the two essential light chains in orange. The head domain contains the actin-binding domain and the ATPase domain. Transition 
to the coiled-coil rod domain is shown at amino acid residue K835 (lysine, position 835). Transition to the non-helical extension of the rod domain 
occurs at P1927 (proline, position 1927). Below:  MYH9 exon structure for the most typical mRNA variant, which is 7.5  kb in size and contains 41 exons. 
The first exon is non-coding (shown in white), and most of the 41st exon is non-coding (shown in white). Exons 2 – 17 encode the head domain and 
are shown in gray. Exons 18 – 41 encode the rod domain, shown in blue. Mutations in the non-helical tail are shown in purple. Shown are 39  MYH9 
variants associated with disease. Most are mutations, but not all variants have been proven to cause disease, as some individuals have two variants 
and the pathogenic roles for both variants have not been established. Data from ref. 6; in that reference the coding exons are numbered from 1 to 40. 
Abbreviations: del, deletion; dup, duplication; fs, frameshift; X, stop codon. (Adapted from a figure graciously provided by Dr. M. Vicente-Manzanares.) 
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 diathesis. Th e reports of renal histology 
obtained from 14 ADM9 patients have 
shown a range of fi ndings, summarized 
in  Table 1 . 1,10 – 18 To be sure, this compil-
ation may not include all published cases 
and has major shortcomings: multiple 
pathologists reading the biopsies, brief 
descriptions, and varied terminologies. 
Nevertheless, there may be important 
lessons that can be learned. Recurring 
features under light microscopy include 
mesangial proliferation (6 / 14),  segmental 
glomerulosclerosis (5 / 14) and variable 
tubulointerstitial disease. Recurring 
 features under electron microscopy, 
which was reported from 11 patients, 
including glomerular GBM thickening 
(6 / 11), splitting (6 / 11), and attenuation 
(2 / 11), so that 9 out of 11 manifested 
some abnormality of the GBM. 
 Th ree points are worth making about 
these pathologic findings and suggest 
directions for future investigation to 
defi ne molecular mechanisms. 
 Table 1  |  Glomerular fi ndings from renal biopsies obtained from patients with autosomal dominant  MYH9 disorders 
 Reference  Age  Sex 
 Continental 
descent 
 MYH9 
mutation 
 Serum 
creatinine  Proteinuria 
 Light 
microscopy 
 Electron 
microscopy 
 Epstein 
 et al. , 1972 11 
 13  F  European  R702C  0.6  mg / dl  0.2  g / d  Segmental and global 
glomerulosclerosis, 
mesangial proliferation 
 Not performed 
 Clare 
 et al. , 1978 19 
 15  M  European 
(Mexican) 
 ND  1.2  mg / dl  14  g / d  Endocapillary prolif-
eration, mesangial 
expansion, adhesions 
to Bowman ’ s capsule, 
and moderate intersti-
tial fi brosis 
 GBM thickening, 
lamellation 
 Peterson 
 et al. , 1985 16 
 23  M  European  Not 
determined 
 End-stage 
kidney disease 
 Present  Preserved glomeruli 
with increased 
mesangial-cell number 
and matrix 
 GBM thickening, focal 
areas of attenuation; 
focal podocyte foot 
process eff acement 
 Turi  et al. , 
1992 17 
 14  M  European  Not 
determined 
 0.8  mg / dl  1.6 – 4  g / d  Segmental glomeru-
losclerosis and diff use 
mesangial proliferation 
 Focal GBM thickening 
and splitting, foot 
process eff acement 
 Iyori  et al. , 
1995 13 
 14  F  Asian (Japan)  Not 
determined 
  Present  Mild tubular atrophy  Mesangial interposition, 
GBM splitting 
 Moxey-
Mims, 1999 14 
 7  M  African  Not 
determined 
 0.6  mg / dl  1.6 g / m 2  Mild mesangial 
expansion 
 Mesangial-cell 
proliferation and matrix 
expansion, GBM with 
variable thickening and 
basket-weave splitting 
 Naito  et al. , 
1997 15 
 3  F  Asian (Japan)  Not 
determined 
 Not stated  Present  Normal  GBM thickening and 
reticulation of the 
lamina densa 
 Naito  et al. , 
1997 15 
 12  F  Asian (Japan)  Not 
determined 
 Normal  Not stated  Mesangial 
proliferation 
 Partial splitting of GBM 
lamina densa 
 Naito  et al. , 
1997 15 
 15  M  Asian (Japan)  Not 
determined 
 Not stated  Nephrotic  Segmental 
glomerulosclerosis 
 GBM thinning 
 Ghiggeri 
 et al. , 2003 12 
 49  M  European  D1424H  5  mg / dl  Present  Glomerulosclerosis  Nonspecifi c 
 Ghiggeri 
 et al. , 2003 12 
 24  F  European  D1424H  Not stated  Present  Normal  Focal segmental foot 
process eff acement 
 Alhindawi 
 et al. , 2009 10 
 10  M  Asian (Jordan)  Not 
determined 
 eGFR 65  ml /
 min / 1.73  m 2 
 Present  Segmental and global 
glomerulosclerosis 
 Not performed 
 Yap  et al. , 
2009 18 
 17  M  Asian (China)  R702H  2.3  mg / dl  4.5  g / d  Global 
glomerulosclerosis 
 Not performed 
 Sekine  et al. , 
2010 1 
 9  F  Asian (Japan)  R702C  0.4  mg / dl  Present  Mild mesangial-cell 
proliferation and 
expansion 
 Mesangial-cell 
proliferation and matrix 
expansion, focal foot 
process eff acement, 
focal GBM thickening 
 Sekine  et al. , 
2010 1 
 11  Same case as above  0.6  mg / dl  Present  Segmental and global 
glomerulosclerosis 
 Not stated 
 Abbreviations: eGFR, estimated glomerular fi ltration rate; GBM, glomerular basement membrane. Summarized here are the glomerular fi ndings from 15 kidney biopsies 
obtained from 14 patients, representing all identifi ed reports of kidney biopsies obtained from patients with autosomal dominant  MYH9 spectrum disorders (the diagnosis was 
made clinically or genetically).  
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 First, the frequent fi nding of mesangial 
hypercellularity is interesting; whether it is 
due to a direct eff ect of the abnormal  MYH9 
protein on mesangial cells is unknown. 
 MYH9 RNA and protein are expressed by 
mesangial cells, but we have no insight into 
what pathways, direct or indirect, might 
lead to proliferation. Indeed, it is not clear 
that infl ammatory-cell infi ltration has been 
excluded as an explanation for the observed 
hypercellularity. 
 Second, fi ve biopsies showed segmen-
tal glomerulosclerosis, which may be a 
nonspecifi c response to mesangial pro-
liferation (two of these patients also 
showed mesangial proliferation) or to 
reduced nephron mass (one case with 
extensive global glomerulosclerosis may 
represent post-adaptive FSGS). Alterna-
tively, FSGS may represent a manifesta-
tion of podocyte injury ; indeed, 
segmental podocyte foot process eff ace-
ment was present in at least three cases. 
Whether we label this as FSGS depends 
on how narrowly or broadly we defi ne 
this diagnosis. Segmental glomeruloscle-
rosis can be seen in other glomerular 
diseases, including IgA nephropathy, 
with primarily mesangial pathology 20 
and in membranous nephropathy, 
although this may refl ect post-adaptive 
FSGS. 21 Barisoni  et al. have proposed a 
broad defi nition that makes room under 
the FSGS tent for segmental glomerulo-
sclerosis with  GLA mutations (Fabry dis-
ease) and  COL4 mutations (Alport 
syndrome). 22 ADM9 spectrum muta-
tions would then fi t within the subcate-
gory of genetic FSGS, the common 
feature of these diseases being podocyte 
injury that stems from the mutation. It is 
tempting to link these manifestations of 
podocyte injury in ADM9 spectrum dis-
orders with the recently discovered asso-
ciation between  MYH9 kidney risk 
alleles, common among African-descent 
individuals, and FSGS, but in both syn-
dromes our knowledge of disease mech-
anism is minimal. 
 Th ird, the GBM abnormalities, including 
focal thickening, focal attenuation, and 
focal splitting, are striking and closely 
resemble collagen IV mutations in Alport 
syndrome (and they are not seen in  MYH9 
kidney risk variant-associated FSGS). 
Th ese GBM abnormalities raise the possi-
bility that the ADM9 spectrum mutations 
disrupt the ability of the podocyte to pro-
duce extracellular matrix proteins with the 
appropriate amounts and stoichiometry or 
the ability to regulate the incorporation of 
these proteins into the GBM in the process 
of physiologic remodeling. Th is is some-
what surprising, as other mutations in 
podocyte-expressed genes such as  NPHS1 
(nephrin),  NPHS2 (podocin),  ACTN4 (  -
actinin-4), and  TRPC6 are not associated 
with GBM abnormalities, and may suggest 
that  nonmuscle myosin IIA is particularly 
engaged in the cellular processes by which 
podocytes orchestrate GBM assembly and 
remodeling. 
 In conclusion, we are just beginning to 
understand how  MYH9 mutations and 
 MYH9 kidney risk variants lead to such 
diverse glomerular pathology.  In vitro 
studies of podocytes cultured from 
ADM9 spectrum patients and  MYH9 
 kidney risk variants, either obtained by 
kidney biopsy or cultured from urine, 23 
and studies of mice that are heterozygous 
for a  MYH9 -null mutation and mice 
transgenic for the R702C, D1424N, and 
E1841K mutations, currently under way 
(R. Adelstein, personal communication, 
National Heart, Lung and Blood Institute, 
National Institutes of Health), may shed 
light on these processes. 
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